Literature DB >> 24951869

Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats.

Yoshiaki Yamaji1, Tetsuo Nakayama2.   

Abstract

Respiratory syncytial virus (RSV) is a common cause of serious lower respiratory tract illnesses in infants. Natural infections with RSV provide limited protection against reinfection because of inefficient immunological responses that do not induce long-term memory. RSV natural infection has been shown to induce unbalanced immune response. The effective clearance of RSV is known to require the induction of a balanced Th1/Th2 immune response, which involves the induction of cytotoxic T lymphocytes (CTL). In our previous study, recombinant AIK-C measles vaccine strains MVAIK/RSV/F and MVAIK/RSV/G were developed, which expressed the RSV fusion (F) protein or glycoprotein (G). These recombinant viruses elicited antibody responses against RSV in cotton rats, and no infectious virus was recovered, but small amounts of infiltration of inflammatory cells were observed in the lungs following RSV challenge. In the present study, recombinant AIK-C measles vaccine strains MVAIK/RSV/M2-1 and MVAIK/RSV/NP were developed, expressing RSV M2-1 or Nucleoprotein (NP), respectively. These viruses exhibited temperature-sensitivity (ts), which was derived from AIK-C, and expressed respective RSV antigens. The intramuscular inoculation of cotton rats with the recombinant measles virus led to the induction of CD8(+) IFN-γ(+) cells. No infectious virus was recovered from a lung homogenate following the challenge. A Histological examination of the lungs revealed a significant reduction in inflammatory reactions without alveolar damage. These results support the recombinant measles viruses being effective vaccine candidates against RSV that induce RSV-specific CTL responses with or without the development of an antibody response.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24951869     DOI: 10.1016/j.vaccine.2014.06.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.

Authors:  Nicolás M S Gálvez; Jorge A Soto; Alexis M Kalergis
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

2.  Simultaneous Administration of Recombinant Measles Viruses Expressing Respiratory Syncytial Virus Fusion (F) and Nucleo (N) Proteins Induced Humoral and Cellular Immune Responses in Cotton Rats.

Authors:  Yoshiaki Yamaji; Akihito Sawada; Yosuke Yasui; Takashi Ito; Tetsuo Nakayama
Journal:  Vaccines (Basel)       Date:  2019-03-04

3.  Development of Recombinant Measles Virus-Based Vaccines.

Authors:  Michael D Mühlebach; Stefan Hutzler
Journal:  Methods Mol Biol       Date:  2017

Review 4.  Vaccine platform recombinant measles virus.

Authors:  Michael D Mühlebach
Journal:  Virus Genes       Date:  2017-07-14       Impact factor: 2.332

5.  Development of Acquired Immunity following Repeated Respiratory Syncytial Virus Infections in Cotton Rats.

Authors:  Yoshiaki Yamaji; Yosuke Yasui; Tetsuo Nakayama
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

6.  Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus.

Authors:  Akira Higuchi; Hiroko Toriniwa; Tomoyoshi Komiya; Tetsuo Nakayama
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

Review 7.  Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.

Authors:  Aline Baldo; Evanthia Galanis; Frédéric Tangy; Philippe Herman
Journal:  Hum Vaccin Immunother       Date:  2015-12-02       Impact factor: 3.452

Review 8.  Peste des petits ruminants.

Authors:  S Parida; M Muniraju; M Mahapatra; D Muthuchelvan; H Buczkowski; A C Banyard
Journal:  Vet Microbiol       Date:  2015-09-05       Impact factor: 3.293

Review 9.  Measles-derived vaccines to prevent emerging viral diseases.

Authors:  Phanramphoei N Frantz; Samaporn Teeravechyan; Frédéric Tangy
Journal:  Microbes Infect       Date:  2018-02-01       Impact factor: 2.700

Review 10.  Recombinant measles AIK-C vaccine strain expressing heterologous virus antigens.

Authors:  Tetsuo Nakayama; Akihito Sawada; Yoshiaki Yamaji; Takashi Ito
Journal:  Vaccine       Date:  2015-11-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.